A. Negro-Vilar

Angiotensin II and ACTH Release:Site of Action and Potency Relative to Corticotropin Releasing Factor and Vasopressin

The present studies were designed to test, using a combination of in vivo and in vitro paradigms, the potency of angiotensin II (AII) to release ACTH, in relation to that of other neural peptides with corticotropin-releasing activity (CRA), such as synthetic corticotropin releasing factor (CRF), arginine vasopressin (AVP) and oxytocin (OXY); and to determine whether a central or peripheral locus is the primary site of action of the peptide. Injection of AII (1 and 5 micrograms, i.p.) in intact unanesthetized male rats, resulted in an increase in plasma ACTH and beta-endorphin-like immunoreactivity (beta-end-LI) levels after the largest dose. The responses, however, were not as pronounced as those elicited by 0.5 microgram of CRF or 1 micrograms of AVP. Injection of AII (i.v., 1 or 5 micrograms) in centrally blocked rats (pretreated with chlorpromazine-morphine-nembutal) failed to elicit any increase in either ACTH or bet a-end-LI levels, whereas 0.5 microgram of either CRF or AVP increased both hormones several fold. In vitro studies using dispersed anterior pituitary cells obtained from male donor rats showed that AII as well as AIII could increase ACTH release at doses of 10(-8) M or larger. Under the same conditions, CRF and AVP stimulated ACTH release to a greater degree at 10(-10) and 10(-9) M, respectively. On the other hand, OXY was stimulatory at 10(-8) M. Dose-response studies indicated a rank order of CRA as follows: CRF greater than AVP greater than OXY greater than AII = AIII. Both AII and AIII showed additive effects when coincubated with either CRF or AVP.(ABSTRACT TRUNCATED AT 250 WORDS)

Dopamine and norepinephrine stimulate somatostatin release by median eminence fragments in vitro

Abstract The effect of catecholamines on somatostatin release by median eminence (ME) fragments was evaluated using an in vitro incubation system. Adult male rats were used as tissue donors. Somatostatin release was readily detected during short-term incubations (10 and 30 minutes). Dopamine (DA) significantly stimulated somatostatin release during a 30 minute incubation period at the two doses tested (0.6 and 6 μM). Under similar conditions, norepinephrine (NE) stimulated somatostatin release only at the 6 μM dose. Using a shorter incubation period (10 min) and a 6 μM dose, only DA stimulated somatostatin release. The effects of DA and NE were specifically blocked by the in vitro addition of pimozide or phentolamine, respectively, suggesting that dopaminergic and noradrenergic receptors may be present in the somatostatinergic terminals of the ME. The results indicate that both DA and NE may be involved in the regulation of somatostatin secretion.

The role of prostaglandins in the control of gonadotropin and prolactin secretion

Abstract Experimental evidence has recently accumulated indicating that administration of some prostaglandins (PGs), particularly those of the E and F series can evoke release of gonadotropic hormones (LH and FSH) and prolactin (PRL) by the anterior pituitary gland. Rather than acting on the pituitary directly, PGs are thought to exert their effects on the hypothalamus. In the case of LH and FSH they stimulate the release of lutenizing hormone-releasing hormone (LHRH). In the case of PRL, PGEs may act by inhibiting the release of PIF (prolactin-inhibiting factor) and/or by enhancing the release of PRF (prolactin-releasing factor). Pharmacologic inhibition of PG synthesis depresses the PRL release induced by estrogen without reducing pituitary PRL release from TRH. Blockade of PG synthesis also decreases LH release in a variety of circumstances, but does not inhibit the pituitary response to LHRH, thus supporting the concept that PGs may play a physiological role in the neural control of the release of this hormone. At the hypothalamus, PGE2 appears to stimulate LHRH release by acting directly on LHRH-secreting elements located in the medial basal hypothalamic-median eminence region (MBH-ME) and the preoptic-anterior hypothalamic (POA-AHA) areas. Radioimmunoassayable PGE and bicassayable PGF content of the ME of the rat is much greater than that of the MBH. Similarly, in vitro release of PGEs by the ME is several times greater than that of the MBH. In vitro incubation of MEs with norepinephrine (NE) results in PGE ands TI-release by the tissue. Inhibition of PG synthesis with indomethacin prevents not only the elevation in PGE levels induced by NE but also the increase in LHRH release induced by both dopamine (DA) and NE suggesting that PGs are physiologically involved in the process of neurotransmitter induced release of LHRH. Moreover, release of PGEs from the ME is reduced by incubation of the tissue with α-adrenergic or dopaminergic receptor blockers and the in vitro response of the ME LHRH terminals to PGEs is enhanced by in vivo pretreatment with ovarian steroids. In conclusion, these recent observations coupled to the aforementioned findings provide strong evidence in support of a physiological role for PGs in the hypothalamic control of gonadotropin release.

Partial characterization of immunoreactive substance P in the rat pituitary gland

Two distinct carboxy-terminus-directed anti-substance P (SP) sera (R-1C and R-6G) were used to characterize immunoreactive SP (I-SP) in acetic acid extracts of anterior pituitary (AP) and posterior pituitary (PP) glands of adult male rats. The tissue concentrations of I-SP measured by R-1C and R-6G were comparable. The contents of I-SP were 600-1150 pg/AP and 25-52 pg/PP. I-luteinizing hormone releasing hormone and I-somatostatin (I-SOM) were undetectable in AP extracts, but PP extracts contained the equivalents of 325-785 pg I-SOM/gland. Serial dilutions of AP and PP extracts produced displacement curves with both SP antisera that were parallel to the respective synthetic SP standard and hypothalamic extract displacement curves. Gel filtrations of AP and PP extracts on a Sephadex G-25 column produced I-SP peaks eluting in the same fractions as synthetic SP and hypothalamic I-SP. However, the AP I-SP profile also revealed a side peak migrating between the void volume and the major I-SP peak. Neither immunoreactive species in the AP extract were eliminated when eluted with 6.0 M guanidine HCl, a strong denaturing agent. In vitro incubation of paired anterior hemipituitaries for 30 min in the presence of a 56 mM K+ concentration resulted in a significant (p less than .0001), 25-fold increase in the release of I-SP into the incubation medium above the mean control value. Radiofrequency lesions placed in the median eminence-arcuate region of male rats caused a significant (p less than .001) reduction of I-SP in both the AP and PP. These reductions were inversely related to the plasma prolactin values. The elevation in plasma prolactin was taken as an index of completeness of lesions. We conclude that: 1) the rat pituitary contains I-SP as assessed by its immunologic and chromatographic behavior, 2) K+ depolarization is a potent stimulator of the release of AP I-SP in vitro, 3) the ME-arcuate region is important for the maintenance of pituitary I-SP levels in the rat.

Cellular mechanisms of acute estrogen negative feedback on LH secretion: Norepinephrine, dopamine and 5-hydroxytryptamine metabolism in discrete regions of the rat brain

Rats on diestrous day 1 were ovariectomized (OVX) and killed 10 days later. LH was measured by RIA and the metabolism of NE, DA and 5-HT were assayed concurrently in the suprachiasmatic (SCN), medial preoptic (MPO), dorsomedial (DMN), rostral (ANr) and caudal (ANc) arcuate nuclei as well as the median eminence (ME) utilizing HPLC with electrochemical detection. Serum LH increased 10-12 fold 10 days following OVX compared to diestrous controls. The injection of estradiol benzoate (Eb, 20 micrograms in corn oil/rat, SC) did not affect LH concentrations at 30 minutes but decreased serum LH both 60 and 180 min following its administration. OVX caused an increased NE metabolism (estimated by the concentration of the NE metabolite, 3-methoxy-4-hydroxyphenylethylene glycol) in the SCN, MPO, ME, and DMN and a decreased NE metabolism in the ANc compared to diestrous control values. All of these changes were reversed or attenuated 180 minutes following Eb treatment. Observed changes in the DA and 5-HT neuronal systems were more restricted and less dramatic with the largest effects on DA metabolism occurring in the DMN and ME and the clearest changes in 5-HT metabolism occurring in the MPO, ANr, and ANc. The results demonstrate that the inhibition of LH secretion following the injection of Eb to OVX rats is accompanied by changes in metabolism in NE neurons in preoptic (SCN and MPO) and medial (ME, DMN, and ANc) hypothalamic areas, as well as in DA neurons in the DMN and ME, and in 5-HT neurons in the MPO, ANr, and ANc.

Aromatic L-amino acid decarboxylase activity in the rat median eminence, neurointermediate lobe and anterior lobe of the pituitary. Physiological and pharmacological implications for pituitary regulation

Recent evidence demonstrating a direct effect of 5-hydroxytryptamine (5-HT) upon anterior pituitary (AP) hormone secretion has made the question of determining the location of possible sites that could supply 5-HT to the AP an important one. It has been assumed, based on indirect evidence, that aromatic L-amino acid decarboxylase (L-AAD), the enzyme responsible for the conversion of L-5-hydroxytryptophan (5-HTP) to 5-HT as well as L-3,4-dihydroxyphenylalanine (L-dopa) to dopamine (DA), is ubiquitously distributed in most tissues of the body including the AP. The present study examined the ability of the AP and two neural areas anatomically connected to the AP, the neurointermediate lobe (NIL) of the pituitary and the median eminence (ME), to decarboxylate 5-HTP to 5-HT or L-dopa to DA following either the in vitro incubation of the various tissues with 5-HTP or L-dopa or the in vivo administration of 5-HTP to rats treated previously with saline or a peripheral decarboxylase inhibitor, MK 486. The in vivo effects of 5-HTP, alone, or following MK 486 pretreatment were also examined on 5-HT synthesis and metabolism in AP tissues which were transplanted 5 days previously under the renal capsule and were, thus, isolated from central influences that might be regulating 5-HT and 5-hydroxyindole-3-acetic acid (5-HIAA) concentrations in the animals own AP. In addition, the direct radioisotopic measurement of L-AAD activity in the ME, NIL, and AP was also analyzed.(ABSTRACT TRUNCATED AT 250 WORDS)

Angiotensin II increases ACTH release in the absence of endogenous arginine-vasopressin

Recent studies from our laboratory indicate a primary central site of action of Angiotensin II (AII) to release ACTH. The present studies were designed to test whether AII is able to release ACTH in vivo in a similar fashion in intact, cannulated, freely moving Long-Evans (LE) or in vasopressin (AVP)-deficient, Brattleboro (DI) female rats. The in vivo response to AII was compared with that elicited by synthetic CRF. AII injected i.v. (0.4 or 2 micrograms/100 g BW) induced a significant, dose-related increase in plasma ACTH values 5 and 15 min after injection, in both LE and DI rats. CRF given to LE and DI rats at 0.4 micrograms/100 g BW elicited a larger increase in ACTH plasma values than a similar dose of AII, 5 or 15 min after the injection. Moreover, ACTH levels after CRF in DI rats were significantly greater than those obtained in LE controls. In vitro studies using dispersed anterior pituitary cells indicate that the response of cells from either LE or DI rats to AII or AVP (both at 10(-9) and 10(-8)M) was similar. Cells from DI donors were hyperresponsive to CRF (2 X 10(-11) and 10(-10)M) in terms of ACTH release when compared with the response of cells from LE rats. The present results suggest that the presence of AVP is not essential to mediate the central response to AII and that AII may act centrally to stimulate CRF release from the hypothalamus in vivo, which would then enhance ACTH output. The results in the DI rat indicate that the increased response to CRF may be an important compensatory mechanism involved in the regulation of adrenocortical function in the DI rat.

Steroid-monoamine feedback interactions in discrete brain regions using as a model the monosodium glutamate (MSG)-lesioned rat

The present studies examine the effects of neonatal treatment with monosodium glutamate (MSG) on dopamine (DA), 5-hydroxytryptamine (5-HT) and norepinephrine (NE) metabolism in discrete brain regions and correlate them with steroid receptor kinetics in the anterior pituitary (PIT), preoptic hypothalamus (POA) and caudal hypothalamus (HYP), and with steroid negative and positive feedback effects on luteinizing hormone (LH) secretion. Substantial decreases in the neuronal activity of all three amines in the arcuate nucleus, decreased DA and 5-HT metabolism in the suprachiasmatic nucleus and, surprisingly, increased metabolism of 5-HT and NE in the median eminence was observed in adult ovariectomized (OVX), MSG-treated versus OVX, vehicle-treated litter mate controls. Measurement of estradiol receptors in the nuclear and cytosolic fractions of the POA, HYP and PIT from MSG- and vehicle-treated rats killed during diestrus or 2 weeks after OVX revealed no differences. Similarly, no differences in cytosolic progestin receptors between control and MSG unprimed or estradiol-primed, OVX rats or on progestin receptor translocation induced by progesterone in Eb-primed rats were observed. Negative and positive feedback effects of estradiol or the positive feedback of progesterone on LH secretion were not significantly impaired in MSG rats, and indeed, MSG animals actually were hyper-responsive to the administration of the steroids or of luteinizing hormone-releasing hormone. These results indicate that the MSG-induced damage to DA, 5-HT and NE elements observed within several preoptic and hypothalamic nuclei does not impair estrogen and progestin receptor kinetics, nor does it prevent adequate negative or positive steroid feedback responses, if appropriate steroid regimens are employed, and that the impaired gonadal function reported in these animals does not result primarily from inadequate steroid feedback mechanisms.

Cyclic GMP and cyclic AMP levels in median eminence, hypothalamus and pituitary gland of the rat after decapitation or microwave irradiation.

Cyclic AMP and cyclic GMP content of the median eminence (ME), medial basal hypothalamus (MBH), posterior pituitary (PP) and anterior pituitary (AP) of inact male rats was measured by radioimmunoassay following decapitation or exposure to microwave irradiation (MW). Levels of both nucleotides in MW irradiated animals were higher in all three nervous tissues studied than in the AP. Following decapitation cyclic AMP levels increased strikingly in the MBH and ME, slightly in the AP, but remained unchanged in the PP. Cyclic GMP levels increased more markedly in the ME than in the MBH, slightly in the PP and did not change in the AP. The distinct synthesizing capability of the cyclic AMP and cyclic GMP generating systems in the ME, a region rich in neurohormones known to control anterior pituitary function, raises the possibility that these nucleotides are involved in the process of neurohormone secretion by the ME.

Estrogenic feminization of the LH response to orchidectomy: Association with prolonged nuclear estradiol receptor retention and induction of cytoplasmic progestin receptors in brain and pituitary

A sex difference in the LH rise after gonadectomy is clearly observable in the rat. While male rats respond with an early (10-12 h) increase in LH after orchidectomy, a delayed response (2-3 days) is recorded after ovariectomy. In this study we tested the hypothesis that the delayed response to gonadectomy in the E2-treated males is due to a more prolonged retention of E2 (when compared with the corresponding male feedback signal, testosterone) within specific central nuclear receptor sites. Orchidectomized (ORDX) animals implanted with either empty or E2-filled Silastic capsules were sacrificed at 0, 24, 48 and 72 h after ORDX or E2-capsule removal. LH levels in ORDX rats rose several-fold by 24 h, whereas E2-treated, ORDX rats, showed no changes in peripheral LH levels until 72 h after E2-capsule removal. At the time of E2-capsule removal (0 h) large increases in nuclear estradiol receptor (NER) levels were seen in anterior pituitary, preoptic area, and hypothalamus (HYP). Twenty-four hours after E2-capsule removal, NER levels were still high in the 3 areas, and by 48 h NER values had returned to control (ORDX) levels, with the exception of HYP where they were slightly but significantly elevated. The increase in NER, as well as the subsequent decline after E2-capsule removal was paralleled by similar changes in cytosolic progestin receptor (CPR) levels in all three regions. Cytosolic testosterone levels were not changed by the E2-treatment. The results indicate that the feminized response to orchidectomy observed in E2-implanted males is related to a prolonged retention of the E2-receptor in nuclear sites. Further, they indicate that E2-treatment in males, as is the case in females, can induce a marked increase in progestin receptor levels within specific brain regions as well as in the pituitary. The reduction in NER and CPR levels to castrate values precedes the first detectable increase in peripheral LH levels. In conclusion, the pattern of LH rise after gonadectomy in the rat is dependent upon the steroidal milieu at the time of removal of the gonads.